RxDoctor Payments Data

Janet Broom, APRN

Family · Salem, ILNPI 1740297498

Payments from drug & device makers

$6,665in general payments, 2019–2025

Across 444 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$977
  • AstraZeneca$868
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$486
  • Lilly USA, LLC$428
  • GSK$324
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,651100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,665 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$2,349
Medicare patients
117
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide95$115,293
OzempicSemaglutide81$112,383
RybelsusSemaglutide68$102,806
FarxigaDapagliflozin Propanediol104$99,662
EliquisApixaban115$98,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$83,060
JardianceEmpagliflozin46$54,216
MounjaroTirzepatide30$39,346
TradjentaLinagliptin41$36,945
Tresiba Flextouch U-100Insulin Degludec31$31,868
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$31,057
MyrbetriqMirabegron33$24,933
VascepaIcosapent Ethyl29$20,248
XareltoRivaroxaban24$16,798
Incruse ElliptaUmeclidinium Bromide30$16,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$977$215,189149 claims
Lilly USA, LLCTrulicity, Mounjaro$428$154,639125 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$324$140,055177 claims
AstraZenecaFarxiga, Symbicort$868$106,203115 claims
PfizerEliquis$180$98,987115 claims
Boehringer IngelheimJardiance, Tradjenta$40$91,16187 claims
Astellas Pharma US IncMyrbetriq$87$24,93333 claims
Johnson & JohnsonXarelto$205$16,79824 claims
AbbVieLinzess$1,304$12,68423 claims
MerckJanuvia$23$10,53513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Salem

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →